Prenetics Global (NASDAQ:PRE) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Prenetics Global (NASDAQ:PRE - Free Report) to a hold rating in a report released on Saturday morning.

Prenetics Global Trading Up 1.2%

PRE traded up $0.10 during trading hours on Friday, hitting $8.11. The company's stock had a trading volume of 40,102 shares, compared to its average volume of 22,613. The company has a 50-day simple moving average of $7.71 and a 200 day simple moving average of $5.89. The firm has a market capitalization of $98.94 million, a PE ratio of -2.03 and a beta of 0.15. Prenetics Global has a fifty-two week low of $3.09 and a fifty-two week high of $11.99.

Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its quarterly earnings results on Thursday, June 12th. The company reported ($0.80) EPS for the quarter. Prenetics Global had a negative net margin of 115.91% and a negative return on equity of 28.07%. The business had revenue of $17.31 million for the quarter. Research analysts expect that Prenetics Global will post -3.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in Prenetics Global Limited (NASDAQ:PRE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global at the end of the most recent reporting period. Institutional investors and hedge funds own 25.01% of the company's stock.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.